Is bigger better for depression trials? - Liu, Kenneth S.; Snavely, Duane B.; Ball, William A.; Lines, Christopher R.; Reines, Scott A.; Potter, William Z. (Journal of psychiatric research, 2008)
Keywords: Adult; Biological and medical sciences; Clinical trial; Clinical Trials, Phase III as Topic - statistics & numerical data; Depression; Depressive Disorder - drug therapy; Double-Blind Method; Female; Humans; Male; Medical sciences; Methodology. Experimentation; Neuropharmacology; Paroxetine; Paroxetine - therapeutic use; Patient Selection; Pharmacology. Drug treatments; Placebo; Placebos; Psychiatry; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease); Psychology. Psychoanalysis. Psychiatry; Psychopathology. Psychiatry; Psychopharmacology; Randomized Controlled Trials as Topic - methods; Randomized Controlled Trials as Topic - statistics & numerical data; Sample Size; Serotonin Uptake Inhibitors - therapeutic use; Techniques and methods; Time Factors; Treatment effect; Treatment Outcome; Paroxetine; Depression; Clinical trial; Sample size; Placebo; Treatment effect; Mood disorder; Human; Evaluation; Protocols; Serotonin; Methodology; Psychotropic; Multicenter study; Pharmacotherapy; Controlled therapeutic trial; Reuptake inhibitor; Selective serotonin reuptake inhibitor; Treatment; Piperidine derivatives; Neurotransmitter; Antidepressant agent; Comparative study